title: In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results.
abstract: BACKGROUND
  Hepatocellular carcinoma is generally diagnosed at advanced stages, for which only palliative treatments are possible by intra-arterial route or by targeted therapies. Among these treatments, metabolic radiotherapy using (90)-yttrium or (188)Re and sorafenib are two options adopted in monotherapy.
  
  
  METHODS
  We address the question of a possible synergy arising from the combination of these two treatments. Two primary malignant hepatoma cell lines, N1S1 (murine HCC) and HepG2 (human hepatoblastoma) were treated in media containing increasing concentrations of sorafenib with/without (188)Re to assess the cellular toxicities of each treatment alone and in combination. The combination index method was used to look for synergy or additivity.
  
  
  RESULTS
  A synergistic advantage of a treatment combining (188)Re and sorafenib is shown in vitro on hepatoma cell lines.
  
  
  CONCLUSIONS
  This combined approach is promising and now needs to be confirmed by more complex in vitro models integrating the tumoral stroma, as well as by in vivo studies.
authors.affiliation: Medical Information, Centre Eugène Marquis, CS 44229 - 35042 Rennes Cedex, France. o.audrain@rennes.unicancer.fr.
authors.forename: Marc
authors.initials: M
authors.lastname: Pracht
authors.forename: Julien
authors.initials: J
authors.lastname: Edeline
authors.forename: Nicolas
authors.initials: N
authors.lastname: Lepareur
authors.forename: Laurence
authors.initials: L
authors.lastname: Lenoir
authors.forename: Valerie
authors.initials: V
authors.lastname: Ardisson
authors.forename: Bruno
authors.initials: B
authors.lastname: Clement
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Raoul
authors.forename: Odile
authors.initials: O
authors.lastname: Audrain
authors.forename: Evelyne
authors.initials: E
authors.lastname: Boucher
authors.forename: Etienne
authors.initials: E
authors.lastname: Garin
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000532:radiotherapy*; D002460:Cell Line; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D006801:Humans; D066298:In Vitro Techniques; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D051379:Mice; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011868:Radioisotopes / Q000494:pharmacology*; D012211:Rhenium / Q000494:pharmacology*; D000077157:Sorafenib
chemical_list: D010671:Phenylurea Compounds; D011868:Radioisotopes; D009536:Niacinamide; D012211:Rhenium; D000077157:Sorafenib
keywords: HepG2 cells; N1S1; Sorafenib; hepatocellular carcinoma; metabolic 188rhenium; radiotherapy; synergy